Experimental pill aims to tame rare, Tough-to-Treat cancer
NCT ID NCT02098538
Summary
This study tested whether an oral medication called regorafenib could help control advanced adenoid cystic carcinoma, a rare cancer. It involved 38 adults whose cancer had returned or spread and was no longer treatable with surgery or radiation. Researchers gave patients a lower starting dose to try to reduce side effects, with the possibility of increasing it later, to see if the drug could slow or stop tumor growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
-
Memorial Sloan Kettering at Mercy Medical Center
Rockville Centre, New York, United States
Conditions
Explore the condition pages connected to this study.